What we're reading, August 5, 2016: judge assigned to Anthem-Cigna and Aetna-Humana cases said he would likely only rule on one by the end of 2016; aversion to late-term abortion plummets when Zika infection is a factor; and the National Institutes of Health proposes lifting ban on research funds for human-animal stem cell research.
A judge responsible for deciding if the government can block the proposed mergers of Aetna-Humana and Anthem-Cigna has indicated both cases are unlikely to be decided by the end of the year. According to Reuters, the judge has said it would be difficult for him to decide both cases by the end of the year and he might send one case back for reassignment. Anthem’s lawyer indicated that no ruling for their case by the end of 2016 might put the deal in jeopardy, and Aetna’s lawyer is pushing for his case to be heard first since the deal was announced first.
Americans’ aversion to late-term abortion plummets in the case pregnant women infected with the Zika virus, a STAT-Harvard poll found. Typically, only 23% of the general American public favors abortion after 24 weeks, but when the possibility of microcephaly from Zika infection enters the equation, approval for late-term abortion jumped to 59%. Even among Republicans, support for late-term abortion was significantly higher (48% compared with 12% normally). The poll also asked about which presidential candidate people thought would do a better job handling the Zika outbreak.
The National Institutes of Health (NIH) is proposing to lift the ban on research funds for human-animal stem cell research. NIH had imposed a ban because these experiments could raise ethical concerns, but a new policy would let scientists receive federal money to make animal embryos that are partly human under carefully monitored conditions, reported NPR. The embryos would be used to create animal models of human diseases and hope to also produce animals with human organs to be used for transplants.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More